{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:35:28Z","timestamp":1786980928033,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Project of Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]},{"name":"the Project of Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]},{"name":"the Project of Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]},{"name":"the Project of Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]},{"name":"the Project of Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]},{"name":"the Project of Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]},{"name":"the Project of Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]},{"name":"the Project of Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]},{"name":"the Project of Sichuan Science and Technology Program","award":["2022YFS0622"],"award-info":[{"award-number":["2022YFS0622"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"DOI":"10.1007\/s10637-024-01468-6","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T16:27:49Z","timestamp":1734452869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of the combination of envafolimab and lenvatinib in unresectable hepatocellular carcinoma: a single-arm, multicentre, exploratory phase II clinical study"],"prefix":"10.1007","author":[{"given":"Yi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunwei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"issue":"3","key":"1468_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality. CA Cancer J Clin. 71(3):209\u201349","journal-title":"CA Cancer J Clin."},{"issue":"5","key":"1468_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","volume":"135","author":"C Xia","year":"2022","unstructured":"Xia C, Dong X, Li H, Cao M, Sun D, He S et al (2022) Cancer statistics in China and United States, 2022: profiles, trends, and. Chin Med J 135(5):584\u201390","journal-title":"Chin Med J"},{"issue":"9972","key":"1468_CR3","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","volume":"385","author":"C Allemani","year":"2015","unstructured":"Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS et al (2015) Global surveillance of cancer survival 1995\u20132009: analysis of individual data for. Lancet 385(9972):977\u20131010","journal-title":"Lancet"},{"issue":"3","key":"1468_CR4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","volume":"162","author":"GL Su","year":"2022","unstructured":"Su GL, Altayar O, O\u2019Shea R, Shah R, Estfan B, Wenzell C et al (2022) AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology 162(3):920\u201334","journal-title":"Gastroenterology"},{"issue":"4","key":"1468_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W et al (2023) Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 20(4):203\u201322","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"4","key":"1468_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1055\/s-0038-1673621","volume":"38","author":"YY Lin","year":"2018","unstructured":"Lin YY, Tan CT, Chen CW, Ou DL, Cheng AL, Hsu C (2018) Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular. Semin Liver Dis 38(4):379\u201388","journal-title":"Semin Liver Dis"},{"issue":"4","key":"1468_CR7","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu J, Shen J, Gu S, Zhang Y, Wu L et al (2021) Camrelizumab in Combination with Apatinib in Patients with Advanced. Clin Cancer Res 27(4):1003\u201311","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1468_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jhep.2021.05.017","volume":"76","author":"A Vogel","year":"2022","unstructured":"Vogel A, Saborowski A (2022) Medical therapy of HCC. J Hepatol 76(1):208\u201310","journal-title":"J Hepatol"},{"issue":"4","key":"1468_CR9","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2022) Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab. J Hepatol 76(4):862\u201373","journal-title":"J Hepatol"},{"issue":"3","key":"1468_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19(3):151\u201372","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1468_CR11","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/14712598.2022.2125799","volume":"22","author":"M Chen","year":"2022","unstructured":"Chen M, Jiang M, Wang X, Shen L, Li J (2022) Envafolimab - first PD-1\/PD-L1 antibody to be administered by subcutaneous. Expert Opin Biol Ther. 22(10):1227\u201332","journal-title":"Expert Opin Biol Ther."},{"issue":"10","key":"1468_CR12","first-page":"898","volume":"45","author":"RR Liu","year":"2023","unstructured":"Liu RR, Gu SZ, Zhou T, Lin LZ, Chen WC, Zhong DS et al (2023) [A phase I study of subcutaneous envafolimab (KN035) monotherapy in Chinese. Zhonghua Zhong Liu Za Zhi 45(10):898\u2013903","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"9","key":"1468_CR13","doi-asserted-by":"publisher","first-page":"e1514","DOI":"10.1002\/onco.13817","volume":"26","author":"KP Papadopoulos","year":"2021","unstructured":"Papadopoulos KP, Harb W, Peer CJ, Hua Q, Xu S, Lu H et al (2021) First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain. Oncologist 26(9):e1514\u2013e25","journal-title":"Oncologist"},{"issue":"1","key":"1468_CR14","doi-asserted-by":"publisher","first-page":"021","DOI":"10.1186\/s13045-021-01095-1","volume":"14","author":"J Li","year":"2021","unstructured":"Li J, Deng Y, Zhang W, Zhou AP, Guo W, Yang J et al (2021) Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch. J Hematol Oncol 14(1):021\u201301095","journal-title":"J Hematol Oncol"},{"issue":"11","key":"1468_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2174\/1568009622666220428111327","volume":"22","author":"J Guo","year":"2022","unstructured":"Guo J, Zhao J, Xu Q, Huang D (2022) Resistance of Lenvatinib in Hepatocellular Carcinoma. Curr Cancer Drug Targets 22(11):865\u201378","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"1468_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40265-019-01116-x","volume":"79","author":"ZT Al-Salama","year":"2019","unstructured":"Al-Salama ZT, Syed YY, Scott LJ (2019) Lenvatinib: A Review in Hepatocellular Carcinoma. Drugs 79(6):665\u201374","journal-title":"Drugs"},{"issue":"4","key":"1468_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u201390","journal-title":"N Engl J Med"},{"issue":"10126","key":"1468_CR18","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391(10126):1163\u20131173","journal-title":"Lancet"},{"key":"1468_CR19","doi-asserted-by":"publisher","first-page":"188391","DOI":"10.1016\/j.bbcan.2020.188391","volume":"1","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Zhang YN, Wang KT, Chen L (2020) Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to. Biochim Biophys Acta Rev Cancer. 1:188391","journal-title":"Biochim Biophys Acta Rev Cancer."},{"issue":"11","key":"1468_CR20","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.neo.2014.09.008","volume":"16","author":"A Wiegering","year":"2014","unstructured":"Wiegering A, Korb D, Thalheimer A, K\u00e4mmerer U, Allmanritter J, Matthes N et al (2014) E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates. Neoplasia 16(11):972\u201381","journal-title":"Neoplasia"},{"issue":"5","key":"1468_CR21","first-page":"2225","volume":"39","author":"SM Ferrari","year":"2018","unstructured":"Ferrari SM, Bocci G, Di Desidero T, Elia G, Ruffilli I, Ragusa F et al (2018) Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro. Oncol Rep 39(5):2225\u201334","journal-title":"Oncol Rep"},{"issue":"12","key":"1468_CR22","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kato YU, Ozawa Y, Kodama K, Ito J, Ichikawa K et al (2018) Immunomodulatory activity of lenvatinib contributes to antitumor activity in the. Cancer Sci 109(12):3993\u20134002","journal-title":"Cancer Sci"},{"issue":"26","key":"1468_CR23","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M et al (2020) Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable. J Clin Oncol 38(26):2960\u201370","journal-title":"J Clin Oncol"},{"issue":"2","key":"1468_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40265-022-01671-w","volume":"82","author":"A Markham","year":"2022","unstructured":"Markham A (2022) Envafolimab: First Approval. Drugs 82(2):235\u201340","journal-title":"Drugs"},{"issue":"2","key":"1468_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ol.2023.13937","volume":"26","author":"S Fan","year":"2023","unstructured":"Fan S, Gai C, Li B, Wang G (2023) Efficacy and safety of envafolimab in the treatment of advanced dMMR\/MSI-H solid. Oncol Lett. 26(2):1","journal-title":"Oncol Lett."},{"issue":"10","key":"1468_CR26","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2217\/fon-2020-0758","volume":"17","author":"PR Galle","year":"2021","unstructured":"Galle PR, Dufour JF, Peck-Radosavljevic M, Trojan J, Vogel A (2021) Systemic therapy of advanced hepatocellular carcinoma. Future Oncol 17(10):1237\u201351","journal-title":"Future Oncol"},{"issue":"3","key":"1468_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10555-023-10084-4","volume":"42","author":"Y Wang","year":"2023","unstructured":"Wang Y, Deng B (2023) Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Cancer Metastasis Rev 42(3):629\u201352","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"1468_CR28","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/14737140.2021.1882855","volume":"21","author":"A Vogel","year":"2021","unstructured":"Vogel A, Bathon M, Saborowski A (2021) Advances in systemic therapy for the first-line treatment of unresectable HCC. Expert Rev Anticancer Ther 21(6):621\u20138","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10126","key":"1468_CR29","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable. Lancet 391(10126):1163\u201373","journal-title":"Lancet"},{"issue":"27","key":"1468_CR30","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1200\/JCO.21.00163","volume":"39","author":"S Qin","year":"2021","unstructured":"Qin S, Bi F, Gu S, Bai Y et al (2021) Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic. J Clin Oncol 39(27):3002\u201311","journal-title":"J Clin Oncol"},{"issue":"1","key":"1468_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY et al (2018) Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379(1):54\u201363","journal-title":"N Engl J Med"},{"issue":"7","key":"1468_CR32","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously. Lancet Oncol 19(7):940\u201352","journal-title":"Lancet Oncol"},{"issue":"3","key":"1468_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19(3):329\u201338","journal-title":"Semin Liver Dis"},{"issue":"6","key":"1468_CR34","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3748\/wjg.v29.i6.1054","volume":"29","author":"M Ds","year":"2023","unstructured":"Ds M, Sk M, Hb C (2023) Immunotherapy for hepatocellular carcinoma: Current status and future. World J Gastroenterol 29(6):1054\u20131075","journal-title":"World J Gastroenterol"},{"issue":"20","key":"1468_CR35","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382(20):1894\u2013905","journal-title":"N Engl J Med"},{"issue":"5","key":"1468_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and. Nat Rev Clin Oncol 15(5):325\u201340","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"1468_CR37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M et al (2023) Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced. Lancet Oncol 24(12):1399\u2013410","journal-title":"Lancet Oncol"},{"issue":"10408","key":"1468_CR38","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X et al (2023) Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for. Lancet 402(10408):1133\u201346","journal-title":"Lancet"},{"issue":"5","key":"1468_CR39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10637-022-01287-7","volume":"40","author":"T Shimizu","year":"2022","unstructured":"Shimizu T, Nakajima TE, Yamamoto N, Yonemori K, Koyama T, Kondo S et al (2022) Phase I study of envafolimab (KN035), a novel subcutaneous single-domain. Invest New Drugs 40(5):1021\u201331","journal-title":"Invest New Drugs"},{"key":"1468_CR40","doi-asserted-by":"publisher","first-page":"1126769","DOI":"10.3389\/fonc.2023.1126769","volume":"13","author":"L Wang","year":"2023","unstructured":"Wang L, Mou H, Hou X, Liao Q (2023) Case report: A case of complete clinical response in a patient experiencing high. Front Oncol 13:1126769","journal-title":"Front Oncol"},{"issue":"11","key":"1468_CR41","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1080\/17512433.2021.1958674","volume":"14","author":"M Catalano","year":"2021","unstructured":"Catalano M, Casadei-Gardini A, Vannini G, Campani C, Marra F, Mini E et al (2021) Lenvatinib: established and promising drug for the treatment of advanced. Expert Rev Clin Pharmacol 14(11):1353\u201365","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"1468_CR42","doi-asserted-by":"publisher","first-page":"0212513","DOI":"10.1371\/journal.pone.0212513","volume":"14","author":"YU Kato","year":"2019","unstructured":"Kato YU, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y et al (2019) Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells. PLoS One 14(2):0212513","journal-title":"PLoS One"},{"issue":"2","key":"1468_CR43","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jhep.2023.03.003","volume":"79","author":"L Rimassa","year":"2023","unstructured":"Rimassa L, Finn RS, Sangro B (2023) Combination immunotherapy for hepatocellular carcinoma. J Hepatol 79(2):506\u201315","journal-title":"J Hepatol"},{"issue":"5","key":"1468_CR44","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1007\/s12072-022-10391-y","volume":"16","author":"K Su","year":"2022","unstructured":"Su K, Liu Y, Wang P, He K, Wang F, Chi H et al (2022) Heat-shock protein 90\u03b1 is a potential prognostic and predictive biomarker in. Hepatol Int 16(5):1208\u201319","journal-title":"Hepatol Int"},{"issue":"1","key":"1468_CR45","doi-asserted-by":"crossref","first-page":"020","DOI":"10.1038\/s41598-019-56924-8","volume":"10","author":"G Wang","year":"2020","unstructured":"Wang G, Lu X, Du Q, Zhang G, Wang D, Wang Q et al (2020) Diagnostic value of the \u03b3-glutamyltransferase and alanine transaminase ratio. Sci Rep 10(1):020\u201370241","journal-title":"Sci Rep"},{"issue":"15","key":"1468_CR46","doi-asserted-by":"publisher","first-page":"14271","DOI":"10.1007\/s00432-023-05089-z","volume":"149","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Guo L, Han L, Li H, Li C, Wen L et al (2023) Thymidine kinase 1 appears to be a marker for the prognosis of hepatocellular. J Cancer Res Clin Oncol 149(15):14271\u201382","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"1468_CR47","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1499-3872(15)60396-4","volume":"14","author":"L Wang","year":"2015","unstructured":"Wang L, Yao M, Pan LH, Qian Q, Yao DF (2015) Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 14(4):361\u20136","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"2","key":"1468_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S1499-3872(13)60028-4","volume":"12","author":"M Yao","year":"2013","unstructured":"Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD et al (2013) Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with. Hepatobiliary Pancreat Dis Int 12(2):171\u20139","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"4","key":"1468_CR49","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1136\/jitc-2020-001875","volume":"9","author":"L Sun","year":"2021","unstructured":"Sun L, Gao F, Gao Z, Ao L, Li N, Ma S et al (2021) Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in. J Immunother Cancer 9(4):2020\u2013001875","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1468_CR50","doi-asserted-by":"publisher","first-page":"021","DOI":"10.1186\/s12885-021-08138-3","volume":"21","author":"H Feng","year":"2021","unstructured":"Feng H, Li B, Li Z, Wei Q, Ren L (2021) PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis. BMC Cancer 21(1):021\u201308138","journal-title":"BMC Cancer"},{"issue":"2","key":"1468_CR51","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3350\/cmh.2022.0212","volume":"29","author":"BN Toan","year":"2023","unstructured":"Toan BN, Tan CK, Hasan I, Setiawan L, Yu ML et al (2023) Utility of combining PIVKA-II and AFP in the surveillance and monitoring of. Clin Mol Hepatol 29(2):277\u201392","journal-title":"Clin Mol Hepatol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01468-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01468-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T18:02:13Z","timestamp":1734458533000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01468-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":51,"alternative-id":["1468"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01468-6","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval of the research protocol by an Institutional Reviewer Board: This study was approved by the Ethics Committee of The Affiliated Hospital of Southwest Medical University (approval number KY2021297). The clinical trial registration number is ChiCTR2200055407.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Yes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The clinical trial registration number is ChiCTR2200055407.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration No. of the study\/trial"}},{"value":"No.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}